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The effect of prednisolone and rifampin, alone and in combination, on the
biodisposition of isoniazid in slow and rapid inactivators of isoniazid was investi-
gated. In one investigation, we made serial determinations of plasma isoniazid
concentrations up to 8 h and of isoniazid and acetylisoniazid in excreted urine up
to 8.5 h in patients receiving isoniazid alone on one occasion and isoniazid plus
prednisolone or isoniazid plus rifampin on another. Prednisolone caused a signifi-
cant decrease in the plasma isoniazid concentrations in both slow and rapid
inactivators. It also enhanced the renal clearance of isoniazid in both slow and
rapid inactivators and increased the rate of acetylation of isoniazid in slow
inactivators only. Rifampin had no effect on the biodisposition of isoniazid in
either slow or rapid inactivators. In a second investigation, one group of slow and
rapid inactivators received isoniazid and rifampin, and a different group received
prednisolone, in addition. Plasma isoniazid concentrations in slow inactivators
receiving prednisolone were significantly lower than in those who received isoni-
azid and rifampin only. In rapid inactivators, plasma isoniazid concentrations
were similar in the two groups of patients, suggesting that concomitant adminis-
tration of rifampin had considerably modified the prednisolone effect on the
biodisposition of isoniazid in these patients.
Corticosteroids are known to affect the bio-
disposition of a number of drugs (17). They have
been shown to inhibit the metabolism of pethi-
dine, promaxine (5) and cyclophosphamide (11) ,
and to affect the renal clearance of salicylates
(14). Similarly, rifampin, a known inducer of the
hepatic microsomal enzyme system, has been
shown to affect the metabolism of cardiac gly-
cosides (16), corticosteroids (3, 6), and dapsone
(10). In a recent controlled clinical trial in. the
treatment of pulmonary tuberculosis with short-
course regimens at our Centre, rifampin was
used in combination with isoniazid, streptomy-
cin, and pyrazinamide. To investigate the role of
corticosteroids in the treatment of tuberculosis,
we used prednisolone as an adjuvant to chemo-
therapy in half the patients admitted to the
study. As part of our program to study multiple-
drug pharmacokinetic interactions in the chemo-
therapy of tuberculosis, we investigated the ef-
fect of prednisolone and rifampin, alone and in
combination, on serial plasma isoniazid concen-
trations and excretion of isoniazid and acetyl-
isoniazid in urine; this paper presents the results
of our investigations.
† Present address: Institute for Research in Medical Statis-
tics, Madras, India.
MATERIALS AND METHODS
Subjects. The subjects were ambulatory South In-
dian patients under treatment at this Centre, with a
mean body weight of 39 kg (95% range: 27 to 51 kg).
They had been previously classified as slow or rapid
inactivators of isoniazid on the basis of standard pro-
cedures described earlier (13, 18).
Investigation I. Isoniazid (10 mg/kg) was admin-
istered to 13 slow and 13 rapid inactivators on the day
they were admitted to the clinical study, and serial
plasma isoniazid concentrations were determined up
to 8 h. At 5 or 6 days, isoniazid (10 mg/kg) plus 20 mg
of prednisolone was administered to the same patients,
and serial plasma isoniazid concentrations were deter-
mined at the same times. On both occasions, urine
excreted over the period 0 to 0.5 h and then hourly up
to 8.5 h was collected, and concentrations of isoniazid
and acetylisoniazid were determined.
The effect of rifampin on the biodisposition of iso-
niazid in 14 slow and 12 rapid inactivators was inves-
tigated in a similar manner. The same patient was
tested twice, after administration of isoniazid (10 mg/
kg) on the day of admission, and 5 or 6 days later, after
a dose of isoniazid (10 mg/kg) plus rifampin (12 mg/
kg). On both occasions, we determined plasma isonia-
zid concentrations serially up to 8 h and isoniazid and
acetylisoniazid concentrations in urine excreted over
the period 0 to 0.5 h and then hourly up to 8.5 h.
Investigation II. At 5 or 6 days after the admission
of the patients to the clinical study, serial plasma
isoniazid concentrations were determined at intervals
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up to 8 h (i) in 25 slow and 27 rapid inactivators after
a dose of isoniazid (10 mg/kg) plus rifampin (12 mg/
kg) and (ii) in a different group of 25 slow and 24 rapid
inactivators after a dose of isoniazid (10 mg/kg) plus
rifampin (12 mg/kg) plus prednisolone (20 mg).
Conduct of the investigations. Isoniazid in inves-
tigation I and isoniazid and rifampin in investigation
II were withheld for 48 h before the start of the test
(there was no interruption of prednisolone). On the
day of the test, a specimen of the patient’s urine was
verified to be negative for acetylisoniazid by the qual-
itative test of Eidus and Hamilton (7), and the drug(s)
was administered under supervision. Blood was col-
lected in heparinized bottles; plasma was separated
immediately and stored at –20°C for not more than
48 h. The volume of the total urine excreted over the
different periods (from patients in investigation I) was
noted, and samples were stored at –20°C for not more
than 3 days. After randomization of the specimens,
plasma and urine isoniazid concentrations were deter-
mined by the method of Rao et al. (19), and acetyli-
soniazid was measured by the method of Raghupati
Sarma et al. (18).
Calculation of pharmacokinetic parameters.
Assuming that elimination of isoniazid follows first-
order kinetics, the rate constant for elimination of
isoniazid and the half-life of isoniazid were calculated
on the basis of the concentrations at 2, 3, 6, and 8 h in
slow inactivators, and at 2, 3, and 6 h only in rapid
inactivators as some of them had indeterminate con-
centrations (<0.2 µg/ml) at 8 h. The geometric mean
of plasma isoniazid concentrations at the various times
was calculated for each patient, and the geometric
mean of these mean values was then computed for
each group. Exposure to isoniazid was calculated as
the area under the time-concentration curve from a
plot of concentration versus time as linear coordinates.
The apparent distribution volume of isoniazid was
calculated by dividing the dose administered (in mil-
ligrams) by the product of exposure to isoniazid and
the rate constant for elimination of isoniazid (4). The
rate constant for acetylation of isoniazid was calcu-
lated by multiplying the first-order rate constant for
elimination of isoniazid with the proportion of dose
excreted as acetylisoniazid in urine collected over the
period 0 to 8.5 h. The renal clearance of isoniazid was
calculated from the concentration of isoniazid in urine
collected during a l-h period and the plasma isoniazid
concentration at the midpoint of that period. The
renal clearance was calculated at 1, 2, 3, and 6 h only,
since at 8 h the plasma isoniazid concentrations were
less than 0.2 µg/ml in some of the rapid inactivators.
RESULTS
Investigation I. The plasma isoniazid con-
centrations in slow and rapid inactivators receiv-
ing isoniazid and isoniazid plus prednisolone are
shown in Fig. 1, and those in patients receiving
isoniazid and isoniazid plus rifampin are shown
in Fig. 2. The geometric mean of plasma isonia-
zid concentration, exposure to isoniazid, and the
half-life of isoniazid were computed for both
slow and rapid inactivators and are shown in
Table 1.
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FIG. 1. Serial plasma isoniazid concentrations
(mean ± standard error of the mean) in slow and
rapid inactivators receiving isoniazid (INH) only or
isoniazid plus prednisolone (PRED).
FIG. 2. Serial plasma isoniazid concentrations
(mean ± standard error of the mean) in slow and
rapid inactivators receiving isoniazid (INH) only or
isoniazid plus rifampin (RIF).
Administration of prednisolone caused a 25%
decrease in plasma isoniazid concentrations in
slow inactivators and a 40% decrease in rapid
inactivators (P < 0.001). The difference in the
magnitude of decrease of isoniazid concentra-
tions between slow and rapid inactivators was
not statistically significant (P > 0.2). Corre-
sponding to the decreased isoniazid levels, ex-
posure to isoniazid in both slow and rapid inac-
tivators and half-life of isoniazid in slow inacti-
vators were significantly smaller in patients who
received prednisolone (P < 0.001). The half-life
of isoniazid was 1.2 h in rapid inactivators re-
ceiving isoniazid only and 1.1 h in the same
patients receiving prednisolone also; the differ-
ence was, however, not statistically significant
(P > 0.2).
Administration of rifampin had no effect on
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TABLE 1. Effect of prednisolone and rifampin on certain pharmacokinetic parameters of isoniazid inpatients
receiving isoniazida
INH
inactivation Drugs No. of
Mean INH Exposure Half-life
administered patients concn
b to INHb of INHb
status (µg/ml) (µg/ml x h) (h)
Slow INH 13 5.10 (3.81-6.83)c 45 (34-60) 2.80 (2.10-3.74)
INH + Pred 3.92 (2.41-6.38) 35 (23-53) 2.24 (1.68-2.99)
INH 14 5.53 (4.31-7.11) 50 (37-67) 3.03 (2.34-3.92)
INH + Rif 5.29 (4.23-6.61) 47 (36-60) 2.82 (2.11-3.77)
Rapid INH 13 2.06 (1.13-3.76) 23 (14-37) 1.20 (0.83-1.74)
INH + Pred 1.28 (0.82-1.99) 16 (11-24) 1.10 (0.91-1.34)
INH 12 2.95 (2.16-4.03) 28 (21-36) 1.65 (1.21-2.25)
INH + Rif 3.12 (2.05-4.75) 29 (21-42) 1.76 (1.19-2.61)
a Abbreviations: INH, isoniazid (10 mg/kg); Pred, prednisolone (20 mg); Rif, rifampin (12 mg/kg).
b Based on the geometric mean of estimates for individual patients.
c Figures in parentheses are the 95% confidence limits.
the mean concentration, exposure, or half-life of
isoniazid in either slow or rapid inactivators
(P > 0.2).
Investigation II. The results of investigation
II are shown in Fig. 3 and Table 2. Administra-
tion of prednisolone to patients receiving isoni-
azid and rifampin significantly decreased the
geometric mean concentration, exposure, and
half-life of isoniazid in slow inactivators; the
magnitude of decrease was of the order of 15%
(P < 0.001). In rapid inactivators, however, there
was no significant effect.
Apparent distribution volume of isonia-
zid. The apparent distribution volume of isoni-
azid in patients receiving isoniazid only was 32
liters in slow inactivators and 33 liters in rapid
inactivators. Since it is not expected that the
effect of prednisolone or rifampin on the appar-
ent distribution volume of isoniazid would be
different in slow and rapid inactivators, findings
in both groups of patients (from investigations
I and II) were amalgamated. The mean values
(not tabulated here) were 32 liters in patients
receiving isoniazid only and 36 liters in those
receiving prednisolone or rifampin or both, in
addition to isoniazid. An analysis of variance
indicated that none of the differences was statis-
tically significant (P > 0.2).
Rate constant for acetylation of isonia-
zid. The rate constant for acetylation of isonia-
zid was calculated using the data from investi-
gation I. In slow inactivators, the rate constant
for acetylation of isoniazid was 0.034 per h with
isoniazid only and 0.059 per h in the same pa-
tients receiving isoniazid plus prednisolone, a
significant difference (P < 0.001). In rapid inac-
tivators, the rate constant for acetylation of iso-
niazid was 0.186 per h with isoniazid only and
0.183 per h with isoniazid plus prednisolone
(P > 0.2).
FIG. 3. Serial plasma isoniazid concentrations
(mean ± standard error of the mean) in slow and
rapid inactivators receiving isoniazid (INH) plus rif-
ampin (RIF) or isoniazid plus rifampin plus prednis-
olone (PRED).
Results (not shown) indicated that rifampin
had no effect on the rate constant for acetylation
of isoniazid in either slow or rapid inactivators.
Renal clearance of isoniazid. The effect of
prednisolone on the renal clearance of isoniazid
(based on data from investigation I) is shown in
Table 3. These findings show that the renal
clearance of isoniazid increased with time and
the mean value obtained at 6 h is approximately
double that obtained at 1 h in both slow and
rapid inactivators. It is also observed that the
renal clearance of isoniazid is broadly similar in
slow and rapid inactivators. Administration of
prednisolone caused a significant increase in the
renal clearance of isoniazid in both slow inacti-
vators (P < 0.001) and rapid inactivators
(P = 0.01).
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Slow INH + Rif 25 5.08 (4.71-5.48)c 44 (42-48) 2.78 (2.62-2.95)
INH + Rif + Pred 25 4.26 (3.94-4.61) 37 (34-40) 2.44 (2.29-2.60)
Rapid INH + Rif 27 1.87 (1.61-2.18) 19 (16-21) 1.37 (1.29-1.46)
INH + Rif + Pred 24 1.98 (1.69-2.32) 21 (18-24) 1.32 (1.22-1.43)
a Abbreviations: INH, isoniazid (10 mg/kg); Rif, rifampin (12 mg/kg); Pred, prednisolone (20 mg).
b Based on the geometric mean of estimates for individual patients.
c Figures in parentheses are the 95% confidence limits.
TABLE 3. Effect of prednisolone on the renal clearance of isoniazid
INH Mean renal clearance (ml/min) at




1 2 3 6 (ml/min)
Slow 13 Isoniaaid 27 35 41 52 37.7
Isoniaaid + prednisolone 33 50 59 66 50.4
Rapid 13 Isoniazid 27 33 53 56 40.5
Isoniazid + prednisolone 31 44 67 76 51.4
a GM, Geometric mean of the renal clearance at 1, 2, 3, and 6 h.
Results (not tabulated here) showed that rif-
ampin had no effect on the renal clearance of
isoniazid. Thus, the mean clearance in slow in-
activators was 33.2 ml/min with isoniazid only
and 33.5 ml/mm with isoniazid plus rifampin;
the corresponding values in rapid inactivators
were 37.2 and 35.3 ml/mm, respectively.
DISCUSSION
Results presented in this paper clearly dem-
onstrate that prednisolone caused an apprecia-
ble decrease in plasma isoniazid concentrations,
leading to lower exposure (area under the time-
concentration curve) and half-life of isoniazid.
This decrease could have been caused by an
enhanced acetylation or renal clearance of iso-
niazid or even by an increase in the total body
water.
The mean body weight of the patients admit-
ted to this study was 39 kg, and the total body
water would therefore be about 28 liters (ap-
proximately 70% of body weight). It has been
shown (9, 12) that the apparent distribution
volume of isoniazid is similar to that of total
body water, and the value calculated from the
findings reported in this paper is approximately
32 liters.
Administration of prednisolone did not cause
any appreciable increase in the apparent distri-
bution volume of isoniazid in either slow or rapid
inactivators. This suggests that the decrease in
plasma isoniazid levels in both groups of patients
is not due to an increase in the total body water
caused by fluid retention due to prednisolone.
The rate constant for acetylation of isoniazid
was five times greater in rapid inactivators than
in slow inactivators, demonstrating that rapid
inactivators acetylate isoniazid five times more
rapidly then slow inactivators, an observation in
agreement with that reported by Ellard and
Gammon (8). In slow inactivators, prednisolone
caused a significant increase in the rate constant
for acetylation of isoniazid, possibly by enhanc-
ing the activity of isoniazid acetyltransferase. In
rapid inactivators, however, prednisolone had no
effect on the rate of acetylation of isoniazid. This
indicates that the effect of prednisolone in in-
creasing the rate of acetylation of isoniazid is
negatively correlated with the concentration of
isoniazid acetyltransferase and, therefore, is not
felt in rapid inactivators who have about five
times as many enzyme molecules as slow inac-
tivators.
The renal clearance of isoniazid (including
acid-labile hydrazones) at 6 h was approximately
double the value at 1 h in both slow and rapid
inactivators. A possible explanation for this in-
crease with time might be that the renal clear-
ance of acid-labile pyruvic and a-ketoglutaric
hydrazones of isoniazid is considerably higher
than that of isoniazid, and it has been observed
that the ratio of these hydrazones to unchanged
isoniazid increases with time (G. A. Ellard, per-
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sonal communication). The mean renal clear-
ance of isoniazid (38 and 40 ml/min in slow and
rapid inactivators) was similar to the values of
41 ml/min reported by Jenne et al. (12) and 46
ml/min reported by Ellard and Gammon (8) in
combined groups of slow and rapid inactivators.
Administration of prednisolone caused a sig-
nificant increase in the renal clearance of isoni-
azid in both slow and rapid inactivators. It is
therefore likely that the decrease in plasma iso-
niazid concentrations in these patients is due to
an increase in the renal clearance of isoniazid.
It may therefore be concluded that predniso-
lone causes an appreciable decrease of plasma
isoniazid concentrations, by enhancing both the
rate of acetylation and the renal clearance of
isoniazid in slow inactivators, and by increasing
the renal clearance only in rapid inactivators.
Administration of rifampin alone did not af-
fect the biodisposition of isoniazid in either slow
or rapid inactivators, a finding in agreement with
those of Acocella et al. (l), Boman (2), and
Modai et al. (15).
Exposure to isoniazid in rapid inactivators
receiving isoniazid plus rifampin in investigation
II (19 µg/ml . h) was significantly lower than in
patients receiving the same drugs in investiga-
tion I (29 µg/ml - h). This is probably due to
genuine differences between the two groups of
patients, for there was corroborative evidence
on another occasion that the former metabolized
isoniazid more rapidly than did the latter.
Results from investigation II show that rif-
ampin had largely counteracted the predniso-
lone effect of lowering plasma isoniazid concen-
trations in rapid inactivators. In slow inactiva-
tors, however, it appears that the effect of pred-
nisolone is maintained even in the presence of
rifampin. Rifampin has been shown to increase
the catabolism of corticosteroids in humans by
induction of steroid-metabolizing enzymes (3,6).
It is therefore likely that rifampin has caused a
more rapid metabolism of the administered
prednisolone leading to an abolition of the pred-
nisolone effect of lowering plasma isoniazid con-
centrations in rapid inactivators. In slow inacti-
vators, who have much less isoniazid acetyl-
transferase than rapid inactivators, it is probable
that even small amounts of prednisolone could
significantly enhance the activity of the acety-
lating enzyme, resulting in decreased plasma
isoniazid levels.
The short-course regimens used in the clinical
trial were highly effective, and there was little
scope for additional therapeutic benefit from the
use of prednisolone (20). On the contrary, the
decrease in plasma isoniazid levels caused by
prednisolone would suggest that steroids may
lower the efficacy of treatment regimens con-
taining isoniazid. The response to treatment was,
however, excellent regardless of whether the
patients received prednisolone or not, suggesting
that such a decrease in plasma isoniazid levels
was not of therapeutic significance. It is, how-
ever, possible that prednisolone may exact a
therapeutic penalty if isoniazid is employed in
lower dosages.
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